Evaluation of the Impact of the Biofield Energy Treated Test Formulation on Various Biomarkers in human Bones, Heart, Liver, Lungs, and Brain Cells

Journal: SM Journal of Public Health and Epidemiology PDF  

Published: July 19, 2019 Volume: 5 Issue: 2

ISSN: 2473-0661

Authors: Victoria Lee Vannes, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak

Citation: Victoria Lee Vannes, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, and Snehasis Jana. Evaluation of the Impact of the Biofield Energy Treated Test Formulation on Various Biomarkers in human Bones, Heart, Liver, Lungs, and Brain Cells. SM J Public Health Epidemiol. 2019; 5(2): 1053.

  • 7 Views
  • Downloads

Abstract

Vital organs dysfunctions are the major concern for human health worldwide. The study aim was to investigate the impact of Biofield Treated test formulation on vital organs function using cell-based assays. The test formulation/test item (TI) and cell media (Med) was divided into two parts; one untreated (UT) and other part received the Biofield Treatment remotely by a renowned Biofield Energy Healer, Victoria Lee Vannes, USA and was labeled as Biofield Treated (BT) test formulation/media. Based on the cell viability test formulation was found safe in six different cells. The test formulation groups showed 112.6% and 108.65% restoration of cell viability in human cardiac fibroblasts cells (HCF); while, 845.63% restoration of cell viability in human hepatoma cells (HepG2) compared to UT-Med + UT-TI group. Furthermore, 131.86% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) than untreated. The alkaline phosphatase (ALP) level was significantly increased by 94.87%, 99.06%, and 105.13% in UT-Med + BT-TI, BT-Med + UTTI, and BT-Med + BT-TI groups, respectively at 10 μg/mL in human bone osteosarcoma cells (MG-63) than untreated. Additionally, ALP level was significantly increased by 150.97%, 382.08%, and 471.4% in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively at 0.1 μg/mL in human endometrial adenocarcinoma cells (Ishikawa) than untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 115.1% (1 μg/mL) and 165.77% (10 μg/mL)in BT-Med + UT-TI and BT-Med + BT-TI, respectively than untreated.

The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 117.65% (1 μg/mL) and 91.3% (63 μg/mL) in UT-Med + BT-TI and BT-Med + BT-TI, respectively than untreated. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 40.56% in UT-Med + BT-TI at 10 μg/mL than untreated. Serotonin level was significantly increased by 543.84% (1 μg/mL), 477.12% (10 μg/mL), and 457.22% (10 μg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BTTI, respectively than untreated. The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 186.96%, 341.43%, and 291.31% in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively at 1 μg/mL than untreated. Overall, these results suggest that Biofield Treated test formulation significantly improved the bones, heart, liver, lungs, and brain-related functional enzyme biomarkers. Therefore, the Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, arrhythmias, heart failure, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, Wilson disease, pneumonia, asthma, emphysema, chronic bronchitis, cystic fibrosis, osteoporosis, etc.

Conclusion

The study outcomes showed that the tested novel Biofield Energy Treated formulation was safe and non-toxic based on MTT cell viability assay in six tested cells. The treatment groups like UTMed + BT-TI and BT-Med + BT-TI showed 112.6% and 108.65% restoration of cell viability in human cardiac fibroblasts cells (HCF) compared to UT-Med + UT-TI group. Moreover, UT-Med + BTTI group showed 845.63% restoration of cell viability at 1 μg/mL in human hepatoma cells (HepG2) compared to untreated. Alkaline phosphatase (ALP) activity was significantly increased by 150.97%, 382.08%, and 471.4% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 0.1 μg/mL in human endometrial adenocarcinoma cells (Ishikawa).The percent protection of HCF cells (decreased of LDH activity) was significantly increased by 76.21% (at 25 μg/mL), 115.1% (at 1 μg/mL), and 165.77% (at μg/mL)in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to the untreated in HCF cells. The percent protection of HepG2 cells (decreased of ALT activity) was significantly increased by 117.65% (at 1 μg/mL) and 91.3% (at 63 μg/mL) in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively compared to untreated group in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 40.56%, 30.14%, and 16.85% in the UTMed + BT-TI group at 10, 25, and 63 μg/mL, respectively compared to untreated in A549 cells. The serotonin level was significantly increased by 543.84% and 438% at 1 μg/mL in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively compared to the untreated in human neuroblastoma cells (SH-SY5Y).The relative quantification (RQ) of vitamin D receptors (VDRs) level was significantly increased by 186.96%, 341.43%, and 291.31% in the UT-Med + BT-TI, BTMed + UT-TI, and BT-Med + BT-TI groups, respectively at 1 μg/mL compared to the untreated in MG-63 cells. In conclusion, The Biofield Energy Treatment significantly improved heart, liver, bones, neuronal, and lungs functional enzyme biomarkers and also protected cardiomyocyte, hepatocyte, osteocytes, pneumocyte, and nerve cells from oxidative damage induced by tert-butyl hydroperoxide (t-BHP). Thus, results suggested that Biofield Energy Treatment can be used as a complementary and alternative treatment for the prevention of various types of cardiac disorders (high blood pressure, stroke, congestive heart failure, peripheral artery disease, congenital heart disease, rheumatic heart disease, valvular heart disease, carditis, thromboembolic disease, and venous thrombosis, etc.), hepatic disorders (cirrhosis, liver cancer, hemochromatosis, Wilson disease), and lungs disorders (Asthma, Chronic bronchitis, Emphysema, Cystic fibrosis, Pneumonia). Further, it can be useful to improve cell-to-cell messaging, normal cell growth and differentiation, cell cycling and proliferation, neurotransmission, skin health, hormonal balance, immune and cardiovascular functions. Moreover, it can also be utilized in organ transplants (i.e., kidney, liver, and heart transplants), hormonal imbalance, aging, and various inflammatory and immunerelated disease conditions like Alzheimer’s Disease (AD), Ulcerative Colitis (UC), Dermatitis, Asthma, Irritable Bowel Syndrome (IBS), Hashimoto Thyroiditis, Pernicious Anemia, Sjogren Syndrome, Multiple Sclerosis, Aplastic Anemia, Hepatitis, Graves’ Disease, Dermatomyositis, Diabetes, Parkinson’s Disease, Myasthenia Gravis, Atherosclerosis, Systemic Lupus Erythematosus (SLE), stress, etc. to improve overall health and Quality of Life.